Trials / Completed
CompletedNCT00238745
Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.
Bone Mineral Density Increase and Safety of TSE-424 Compared to Placebo in Osteoporotic Postmenopausal Women
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 375 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 85 Years
- Healthy volunteers
- Not accepted
Summary
Dose-response in Japanese patients with postmenopausal osteoporosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bazedoxifene | |
| DRUG | Placebo |
Timeline
- Start date
- 2003-08-01
- Completion
- 2007-03-01
- First posted
- 2005-10-13
- Last updated
- 2007-12-20
Source: ClinicalTrials.gov record NCT00238745. Inclusion in this directory is not an endorsement.